Bioretec Oy

Bioretec Oy EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Bioretec Oy (BRETEC.HE) as of Nov 5, 2026 is -0.42. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.43 — a change of -1.81% (higher).

EV/FCF

-0.42

YoY

-1.81%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Bioretec Oy is 2025 -0.42 . EV/FCF (Enterprise Value to Free Cash Flow) of Bioretec Oy was 2024 -0.43 . It decreases by -1.81% higher compared to the previous year.

The Bioretec Oy EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-6.03 EUR
Jan 1, 2019
-8.55 EUR
Jan 1, 2020
-4.04 EUR
Jan 1, 2021
-0.64 EUR
Jan 1, 2022
-3.00 EUR
Jan 1, 2023
-0.59 EUR
Jan 1, 2024
-0.43 EUR
Jan 1, 2025
-0.42 EUR
The Bioretec Oy EV/FCF history
YEAREV/FCFYoY
-0.42-1.81%
-0.43-27.24%
-0.59-80.20%
-3.00+369.38%
-0.64-84.20%
-4.04-52.73%
-8.55+41.93%
-6.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioretec Oy Stock analysis

What does Bioretec Oy do? Bioretec Oy develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics, operating as a developer, manufacturer, and commercializer of innovative bioresorbable orthopedic implants and implant materials. The company's Activa product portfolio includes bioabsorbable biopolymer products available in the market for pediatric, trauma, and sports surgery applications. Bioretec Oy has a Germany-based subsidiary, BRI.Tech GmbH, and its products are used globally across various medical specialties. The company generates revenue through the sale of its Activa product portfolio, targeting healthcare providers and medical institutions worldwide. The Activa products are designed for bone and soft tissue injury treatments, serving segments in pediatrics, trauma surgery, and sports medicine. Bioretec Oy's global distribution network enables the commercialization of its implants in international markets. Bioretec Oy's business model focuses on the development, manufacturing, and commercialization of bioresorbable orthopedic solutions. The company's products are marketed under the Activa brand, catering to medical professionals in specialized surgical fields. The Germany-based subsidiary BRI.Tech GmbH supports the company's operations in the European market. Bioretec Oy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioretec Oy stock

EV/FCF (Enterprise Value to Free Cash Flow) of Bioretec Oy is -0.42 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Bioretec Oy changed from -0.43 to -0.42, representing a -1.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Bioretec Oy since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Bioretec Oy with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bioretec Oy

All Key Metrics — Bioretec Oy